Outcome
Type |
Measure |
Description |
Time frame |
Safety issue |
Primary |
Evaluate quality of life |
Validation of FACT-Leu. Change from baseline (treatment start) of FACT-Leu total score |
Baseline until end of study (during invosidinib treatment and Follow-Up); Up to 54 months |
|
Secondary |
Subjective well-being: Validation of FACT-Leu |
Change from baseline (treatment start) of FACT_Leu subscale score |
Baseline until end of study (during invosidinib treatment and Follow-Up); Up to 54 months |
|
Secondary |
Subjective well-being: Validation of FACT-Leu |
Time to deterioration of FACT-Leu total score |
Baseline until end of study (during invosidinib treatment and Follow-Up); Up to 54 months |
|
Secondary |
Subjective well-being: Validation of FACT-Leu and EQ-5D-5L questionnaire |
Change from baseline and TTD of FACT-G total score |
Baseline until end of study (during invosidinib treatment and Follow-Up); Up to 54 months |
|
Secondary |
Subjective well-being: Validation of FACT-Leu and EQ-5D-5L questionnaire |
Trial Outcome Index |
Baseline until end of study (during invosidinib treatment and Follow-Up); Up to 54 months |
|
Secondary |
Subjective well-being: Validation of EQ-5D-5L questionnaire |
Change from baseline of the EQ-5D-5L visual analogue scale (VAS) |
Baseline until end of study (during invosidinib treatment and Follow-Up); Up to 54 months |
|
Secondary |
Subjective well-being: Validation of EQ-5D-5L questionnaire |
Index value of EQ-5D-5L over time |
Baseline until end of study (during invosidinib treatment and Follow-Up); Up to 54 months |
|
Secondary |
Assesment of effectiveness in routine treatment |
Assesment of overall survival (OS), |
Baseline until end of study (during invosidinib treatment and Follow-Up); Up to 54 months |
|
Secondary |
Assesment of effectiveness in routine treatment |
Event-free survival (EFS) |
Baseline until end of study (during invosidinib treatment and Follow-Up); Up to 54 months |
|
Secondary |
Assesment of effectiveness in routine treatment |
Overall Response Rate (ORR; i.e. CR, CR with incomplete hematologic recovery (Cri), (including CR with incomplete platelet recovery (CRp), CR with partial hematologic recovery (CRh), or partial recovery (PR)), Duration of CR (DOCR), Duration of Response (DOR; CR, Cri, CRp, CRh, PR)) |
Baseline until end of study (during invosidinib treatment and Follow-Up); Up to 54 months |
|
Secondary |
Assesment of effectiveness in routine treatment |
Time to first response (TTR) |
Baseline until end of study (during invosidinib treatment and Follow-Up); Up to 54 months |
|
Secondary |
Assessment of drug safety |
Assesment of adverse events (AEs), serious adverse events (SAEs), adverse drug reactions (ADRs), serious adverse drug reactions (SADRs), Adverse events of special interest (AESIs) |
Baseline until end of study (during invosidinib treatment and Follow-Up); Up to 54 months |
|
Secondary |
Assessment of parameters of treatment decision making |
Frequency of distinct parameters affecting therapy choice including reasons why patient is ineligible for standard induction chemotherapy. |
From date of patient enrollment until start of treatment |
|
Secondary |
Ivosidenib and azacitidine treatment: Dose intensity |
Descriptive statistics will be provided for dose intensity for ivosidinib and azacitidine |
Baseline until end of study (during invosidinib treatment and Follow-Up); Up to 54 months |
|
Secondary |
Ivosidenib and azacitidine treatment: Frequency and type of dose modification |
Frequency tabels will be provided for frequency and type of dose modification for ivosidinib and azacitidine |
Baseline until end of study (during invosidinib treatment and Follow-Up); Up to 54 months |
|
Secondary |
Ivosidenib and azacitidine treatment: Reason for dose modifications |
Frequeny tabels of reasons for dose modifications will be provided for ivosidinib and azacitidine |
Baseline until end of study (during invosidinib treatment and Follow-Up); Up to 54 months |
|
Secondary |
Ivosidenib and azacitidine treatment: Duration of treatment in total and for each substance |
Descriptive statistics will be provided for duration of treatment in total and for each substancedose |
Baseline until end of study (during invosidinib treatment and Follow-Up); Up to 54 months |
|
Secondary |
Ivosidenib and azacitidine treatment: Reason for end of treatment (EOT) |
Frequency tabels of EOT-reasons will be provided |
Baseline until end of study (during invosidinib treatment and Follow-Up); Up to 54 months |
|
Secondary |
Treatment reality in detail: Transfusion dependency |
Proportion of transfusion dependent patients to independency and vice versa will be provided |
Baseline until end of study (during invosidinib treatment and Follow-Up); Up to 54 months |
|
Secondary |
Treatment reality in detail: Concomitant medication |
Frequency table of concomitant medication in total and frequency of concomitant medications known to induce QT prolongation (e.g., antiarrhythmic medicines, fluoroquinolones, triazole anti-fungals, 5-HT3 receptor antagonists) as well as strong CYP3A4 inducers or dabigatran will be provided |
Baseline until end of study (during invosidinib treatment and Follow-Up); Up to 54 months |
|
Secondary |
Treatment reality in detail: Subsequent antineoplastic therapies |
Description of frequency and type of subsequent antineoplastic therapies by line of therapy (number and substance) |
Baseline until end of study (during invosidinib treatment and Follow-Up); Up to 54 months |
|
Secondary |
Treatment reality in detail: Frequency of hospitalizations/emergency room visits |
Frequency tabel of hospitalization and emergency room visits will be provided |
Baseline until end of study (during invosidinib treatment and Follow-Up); Up to 54 months |
|
Secondary |
Treatment reality in detail: Reasons for hospitalizations/emergency room visits |
Frequency tabel of reasons for hospitalization and emergency room visits will be provided |
Baseline until end of study (during invosidinib treatment and Follow-Up); Up to 54 months |
|
Secondary |
Treatment reality in detail: Length of hospital stay |
Descriptive statistic for length of hospital stay will be privided |
Baseline until end of study (during invosidinib treatment and Follow-Up); Up to 54 months |
|